Archive for December, 2010

CAM and Kids: Hazardous to one’s health

http://www.medicalnewstoday.com/articles/212446.php

Medical News Today

Complementary Medicines Only Can Prove Fatal In Children

23 Dec 2010   

“In modern parenthood, administered complementary medicines (CAM) can be dangerous for children, and can even prove fatal if entirely substituted for conventional medicine as the only alternative……According to a study by the Australian Pediatric Surveillance Unit between 2001 and 2003, adults often feel, and are mislead to believe, that CAM treatments are better for children because they are all natural and therefore less likely to have harmful side effects.   During the three year span of this observation, four deaths were reported in association with CAM treatments and 46 instances of negative outcomes. All four reported deaths were related to the substitution of conventional treatment with CAM……..”

Adverse events associated with the use of complementary and alternative medicine in children

by Alissa Lim, Noel Cranswick, Michael South

Arch Dis Child    archdischild183152    Published Online First    22 December 2010

http://adc.bmj.com/content/early/2010/11/24/adc.2010.183152.short

That’s why they’re called ‘placebo’.

http://www.medicalnewstoday.com/articles/212427.php

Medical News Today

Placebos Plus Positive Thinking May Be Enough

23 Dec 2010   

“Placebos, which contain no active ingredients, are typically used as controls for potential new medication clinical trials. It has been confirmed that patients often respond to them based solely on the idea that the act of taking a medication, coupled with a positive mental attitude, may in fact cause the body to heal itself or identify that the original diagnosis was self created ……..

Eighty patients suffering from irritable bowel syndrome…….were divided into two prescribed groups. The controls received no treatment. The second group received placebo cycles which were openly described as such. Subjects were told to take the pills twice per day………

……….Three weeks passed and almost double of the patients treated with the placebo, 59 percent, reported symptom relief as compared to the control group which was only 39 percent. Additionally, patients taking the placebo increased their rates of improvement by double to a relief threshold achieved by some of the most powerful IBS medications on the market. …….”

NYS: New HIV law

From CDC’s Public Health Law News

“HIV test law offers challenge to E.R.s”

Albany Times Union   (12/2/2010)   Cathleen F. Crowley

http://www.timesunion.com/default/article/HIV-test-law-offers-challenge-to-ERs-852303.php

“A new state law went into effect in New York on September 1, 2010, mandating that doctors ask every patient between the ages of 13 and 64 if they want to be tested for HIV. The law also requires that patients who test positive for HIV be given a follow-up appointment with an HIV specialist…..”

 …..Still, some emergency rooms are struggling to implement the new law, especially the follow-up requirement. “What do you do with a positive test at 3 a.m.? Who’s going to follow up?,” asks Dr. Todd Duather, Nathan Littauer Hospital’s chief of emergency medicine…”

 

[Editor’s Note: To read the law, visit http://open.nysenate.gov/legislation/bill/S8227.]

Midazolam vs diphenhydramine & akathisia

A trial of midazolam vs diphenhydramine in prophylaxis of metoclopramide-induced
akathisia
Published online: 15 December 2010
Bulent Erdur, Pinar Tura, Berrin Aydin, Mert Ozen, Ahmet Ergin, Ismet Parlak,
Burhan Kabay
DOI: 10.1016/j.ajem.2010.10.007
American Journal of Emergency Medicine

http://www.ajemjournal.com/article/S0735-6757%2810%2900485-7/abstract

Predictive biomarkers for mortality in STEMI patients after PCI

Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

Peter Damman, Marcel A.M. Beijk, Wichert J. Kuijt, Niels J.W. Verouden, Nan van Geloven, José P.S. Henriques, Jan Baan, Marije M. Vis, Martijn Meuwissen, Jan P. van Straalen, Johan Fischer, Karel T. Koch, Jan J. Piek, Jan G.P. Tijssen, and Robbert J. de Winter

J Am Coll Cardiol 2011;57 29-36

http://content.onlinejacc.org/cgi/content/abstract/57/1/29?etoc

During follow-up (median, 901 days), 120 of the 1,034 patients died. Glucose, estimated glomerular filtration rate, and N-terminal pro-brain natriuretic peptide were the strongest predictors for mortality.

Docs under fire

http://www.mercurynews.com/peninsula/ci_16907403?source=most_viewed&nclick_check=1

Dozen Stanford physicians under fire for speaking at gigs paid for by drugmakers

By Lisa M. Krieger

lkrieger@mercurynews.com

Posted: 12/20/2010 08:29:08 PM PST

Updated: 12/20/2010 11:16:49 PM PST

 

“A dozen physicians at Stanford University’s School of Medicine are under investigation by the school’s disciplinary board for their too-cozy relationships with drug companies……”

More links:  http://www.miamiherald.com/2010/12/20/1982870/drug-firm-fees-to-um-doctors-are.html

Echinacea for a cold? Bah! Humbug!

Annals of Internal Medicine

Randomized, controlled trial.

719 patients, 12 to 80 years of age, with new-onset common cold.

Patients were assigned to 1 of 4 parallel groups: no pills, placebo pills (blinded), echinacea pills (blinded), or echinacea pills (unblinded, open-label).

One outcome:  Mean illness duration in the blinded and unblinded echinacea groups was 6.34 and 6.76 days, respectively, compared with 6.87 days in the blinded placebo group and 7.03 days in the no-pill group.

Source reference:
Barrett B, et al “Echinacea for treating the common cold: a randomized trial” Ann Intern Med 2010; 153: 769-777.

http://www.annals.org/content/153/12/769.abstract

Study’s conclusion:  “Illness duration and severity were not statistically significant with echinacea compared with placebo.”

“Spice”

“Spice” Girls: Synthetic Cannabinoid Intoxication
Published online: 20 December 2010
Aaron B. Schneir, Jennifer Cullen, Binh T. Ly
DOI: 10.1016/j.jemermed.2010.10.014
Journal of Emergency Medicine

http://www.jem-journal.com/article/S0736-4679%2810%2900880-2/abstract

Faculty physicians on the “take”

Med Schools Flunk at Keeping Faculty Off Pharma Speaking Circuit
by Tracy Weber and Charles Ornstein

ProPublica.org

http://www.propublica.org/article/medical-schools-policies-on-faculty-and-drug-company-speaking-circuit

“Top U.S. medical schools and teaching hospitals are failing to adequately enforce policies that prohibit or restrict faculty physicians from being paid by drug companies to give promotional speeches about their products….”

Denufosol & cystic fibrosis

http://www.medpagetoday.com/Pulmonology/CysticFibrosis/23973

Novel Drug Aids CF Kids’ Lungs

MedPage Today

By Crystal Phend, Senior Staff Writer, MedPage Today
Published: December 18, 2010
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine.

“The experimental ion channel-regulating drug denufosol improves children’s lung function early in the course of cystic fibrosis, according to results of the first large phase III trial of the agent.  The randomized trial of more than 350 CF patients age five and older found that the mean forced expiratory volume at one second (FEV1) rose 0.048 L — approximately 2% over baseline — during 24 weeks on denufosol compared with 0.003 L on placebo, (P=0.047)…….”

Primary source: American Journal of Respiratory and Critical Care Medicine
Source reference:
Accurso FJ, et al “Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function” Am J Respir Crit Care Med 2011.

Novel Drug Aids CF Kids’ Lungs

 

 

FDA: Anzemet (dolasetron mesylate) & Reports of Abnormal Heart Rhythms

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237341.htm

Anzemet (dolasetron mesylate): Drug Safety Communication – Reports of Abnormal Heart Rhythms

[Posted 12/17/2010]

AUDIENCE: Oncology, Cardiology

ISSUE: FDA notified healthcare professionals that a contraindication is being added to the prescribing information advising that the injection form of Anzemet (dolasetron mesylate) should no longer be used to prevent nausea and vomiting associated with cancer chemotherapy (CINV) in pediatric and adult patients. New data demonstrate that Anzemet injection can increase the risk of developing torsade de pointes, an abnormal heart rhythm, which in some cases can be fatal. Patients at particular risk are those with underlying heart conditions or those who have existing heart rate or rhythm problems. Anzemet causes a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram.

BACKGROUND: FDA previously noted cardiovascular safety concerns which suggested Anzemet could cause QT prolongation.  However, limitations of the previous data did not clearly establish the degree to which Anzemet may cause QT prolongation. FDA recommended that the drug sponsor conduct a thorough QT study in adults in order to determine the degree of the prolongation. A pediatric study was not recommended due to the wide variability in heart rate and, thus, QTc interval in the pediatric population. See the Data Summary section of the Drug Safety Communication (DSC) for information that supports this change in the prescribing information.

RECOMMENDATION: Anzemet should not be used in patients with congenital long-QT syndrome. Hypokalemia and hypomagnesemia should be corrected before administering Anzemet. These electrolytes should be monitored after administration as clinically indicated. Use electrocardiogram monitoring in patients with congestive heart failure, patients with bradycardia, patients with underlying heart disease, the elderly and in patients who are renally impaired who are taking Anzemet. Anzemet injection may still be used for the prevention and treatment of postoperative nausea and vomiting because the lower doses used are less likely to affect the electrical activity of the heart and result in abnormal heart rhythms.

Anzemet tablets may still be used to prevent CINV because the risk of developing an abnormal heart rhythm with the oral form of this drug is less than that seen with the injection form. However, a stronger warning about this potential risk is being added to the Warnings and Precautions sections of the Anzemet tablet label.

See the DSC for additional recommendations for healthcare professionals and for patients.
 

 

[12/17/2010 - Drug Safety Communication - FDA]

Way to go, Walgreen!

http://www.hhs.gov/news/press/2010pres/12/20101217a.html

News Release

FOR IMMEDIATE RELEASE
Friday, December 17, 2010
Contact: HHS Press Office
(202) 690-6343

HHS and Walgreens Announce New Effort Aimed at Addressing Health Disparities in Flu Vaccination

New effort will provide $10 million worth – approximately 350,000 free flu vaccines to underinsured and underserved

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced that Walgreens has agreed to donate $10 million in vouchers for free flu shots to 350,000 eligible uninsured and underserved people in 15 markets across the country. 

Secretary Sebelius made the announcement earlier today in a conference call with Assistant Secretary for Health Dr. Howard Koh, the Centers for Disease Control and Prevention’s Dr. Dan Jernigan, and Walgreens President of Pharmacy Services, Kermit Crawford.  The announcement is part of a larger demonstration project being undertaken by HHS and its partners to address continuing health disparities in flu vaccination rates. 

“Thanks to the new health care law, many people can get their flu vaccination without paying a co-pay or deductible, but there are still more Americans who cannot afford to get vaccinated for the flu,” said Secretary Sebelius. “With this generous donation, Walgreens is helping individuals and families who otherwise might be unprotected from the flu this season. We are also troubled by recent data showing disparities among people when it comes to flu vaccination. This donation will help us remove barriers that have prevented some from getting vaccinated.”

Vouchers are good for one flu shot at any Walgreens pharmacy, Duane Reade pharmacy in New York or Take Care Clinic, and will be available beginning early next week in the following metropolitan areas:

  • Atlanta, GA
  • Bronx, NY
  • Chicago, IL
  • Houston, TX
  • Kansas City, MO
  • Newark, NJ
  • Oakland, CA
  • Philadelphia, PA
Vouchers will also soon be distributed and available through local health agencies in:
  • Fort Lauderdale, FL 
  • Miami-Dade County, FL
  • Palm Beach, FL
  • Seattle, WA
  • Waco, TX      
  • Washington, D.C.
  • Northern New Hampshire
  • Brooklyn, Queens, Staten Island, NY

Local public health officials and their community partners in the identified cities, in conjunction with the HHS regional health administrators, will distribute the vouchers through a variety of community outreach efforts. Vouchers will be available on a first come, first served basis while supplies last.  State, age and other restrictions may apply. 

Background on the HHS Demonstration Project to Reduce Health Disparities in Flu Vaccinations

Today’s announcement is part of a larger HHS demonstration project with local, state, public and private partners to expand efforts to reduce health disparities in flu vaccination.  Protecting All from Flu – HHS Demonstration Project to Expand Efforts to Reduce Health Disparities in Flu Vaccination targets 15 communities in a coordinated effort to improve influenza vaccination rates among underserved populations.  The communities were selected based on existing vaccination disparities as well as the availability of HHS infrastructure and resources in these areas.

For more information about HHS efforts to promote influenza vaccination across the country, visit: www.flu.gov.

###


Internationally adopted children: A source of highly resistant enteric pathogens?

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5949a3.htm?s_cid=mm5949a3_e

Notes from the Field: Emergence of Shigella flexneri 2a Resistant to Ceftriaxone and Ciprofloxacin — South Carolina, October 2010

December 17, 2010 / 59(49);1619

 

On October 20, 2010, the South Carolina Department of Health and Environmental Control and CDC began investigating a cluster of three diarrheal illnesses caused by multidrug-resistant Shigella flexneri 2a. The index case occurred in a girl aged 2 years who experienced the onset of diarrhea on September 25 and was hospitalized the next day because of a seizure and fever. On September 30, her brother, aged 6 years, was hospitalized with vomiting, bloody diarrhea, and hyponatremia. Three days later, her father was hospitalized with vomiting, bloody diarrhea, and hyponatremia.

S. flexneri 2a was isolated from all three patients and tested for antimicrobial susceptibility using semi-automated broth microdilution panels. Interpretations of susceptible, intermediate, or resistant were based on the most recently approved standards published by the Clinical and Laboratory Standards Institute (1). The isolates were found susceptible to imipenem, had intermediate susceptibility or were resistant to ceftazidime and cefepime, and were resistant to ampicillin, aztreonam, cefotaxime, ceftriaxone, chloramphenicol, ciprofloxacin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim/sulfamethoxazole. Azithromycin inhibited the isolates at a minimum concentration of 2 or 4 µg/mL, which is similar to the azithromycin minimum inhibitory concentrations among Shigellae in the United States during 2005–2007 (no breakpoint for Shigella susceptibility to azithromycin has been established) (2).

The two children were treated sequentially with ceftriaxone, piperacillin/tazobactam, azithromycin, and clarithromycin, for a total of 25 days of treatment per child. The father received piperacillin/tazobactam and azithromycin for 6 days. The younger child’s diarrhea persisted for ≥16 days; Shigella organisms were isolated from every stool specimen tested until 24 days after diarrhea onset. All three patients recovered fully.

The index patient was born in China and lived there until being adopted and brought to the United States in August 2010. A playmate of hers, also adopted from China and believed to be aged 2 years, had diarrhea at approximately the same time as the index patient, but no further information was available. None of the other eight family members of the girl nor any social contacts have reported diarrhea since September 2010.

Besides being associated with severe disease, the S. flexneri isolates were resistant to most clinically useful antibiotics and demonstrated a combination of resistance to extended-spectrum cephalosporins and quinolones rarely seen among Shigella organisms isolated in the United States (3). Transmission of this difficult-to-treat pathogen can be prevented by scrupulous hygiene, including thorough handwashing. Shigellosis therapy should be guided by the results of antimicrobial susceptibility testing, and cases should be reported promptly to public health officials so that control measures can be implemented.

Although the source of these isolates is unknown, internationally adopted children can be a source of highly resistant enteric pathogens (4). When newly arrived adoptees have diarrhea, stool culture for bacterial pathogens should be strongly considered (5).

References

  1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement (June 2010 update). CLSI document M100-S20-U. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
  2. Howie RL, Folster JP, Bowen A, Barzilay EJ, Whichard JM. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb Drug Resist 2010;16:245–8.
  3. CDC. National Antimicrobial Resistance Monitoring System: enteric bacteria. Human isolates final report, 2008. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/narms/annual/2008/narms_2008_annual_report.pdf Adobe PDF file. Accessed December 10, 2010.
  4. Hendriksen RS, Mikoleit M, Kornschober C, et al. Emergence of multidrug-resistant Salmonella Concord infections in Europe and the United States in children adopted from Ethiopia, 2003–2007. Pediatr Infect Dis J 2009;28:814–8.
  5. American Academy of Pediatrics. Shigella infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2009 report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:593–6.

 

Weekly

Resettled Iraqi Refugees : How sick are they?

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5949a2.htm?s_cid=mm5949a2_e

Health of Resettled Iraqi Refugees — San Diego County, California, October 2007–September 2009

MMWR Weekly

 

December 17, 2010 / 59(49);1614-161

In recent years, Iraqi refugees have been resettling in the United States in large numbers, with approximately 28,000 arrivals during October 2007–September 2009 (federal fiscal years [FYs] 2008 and 2009). All refugees undergo a required medical examination before departure to the United States to prevent importation of communicable diseases, including active tuberculosis (TB), as prescribed by CDC Technical Instructions (1). CDC also recommends that refugees receive a more comprehensive medical assessment after arrival, which typically occurs within the first 90 days of arrival. To describe the health profile of resettled Iraqi refugees, post-arrival medical assessment data were reviewed for 5,100 Iraqi refugees who underwent full or partial assessments at the San Diego County refugee health clinic during FYs 2008 and 2009. Among 4,923 screened refugees aged >1 year, 692 (14.1%) had latent tuberculosis infection (LTBI); among 3,047 screened adult refugees aged >18 years, 751 (24.6%) were classified as obese; and among 2,704 screened adult refugees, 410 (15.2%) were hypertensive. Although infectious illness has been the traditional focus of refugee medical screening (2), a high prevalence of chronic, noninfectious conditions that could lead to serious morbidity was observed among Iraqi refugees. Public health agencies should be aware of the potentially diverse health profiles of resettling refugee groups. Medical assessment of arriving refugee populations, with timely collection and review of health data, enables early detection, treatment, and follow-up of conditions, and can help public health agencies develop and set priorities for population-specific health interventions and guidelines.

During FYs 2008 and 2009, California received 24% (6,626) of all U.S.-bound Iraqi refugees, the largest proportion of any state (Figure). The California Refugee Health Program provides comprehensive, standardized medical assessments for all refugees within 90 days of arrival. Based on those assessment results, refugees are referred to primary-care providers and, if needed, for specialized care. This initial assessment, based partially on CDC guidelines for arriving refugees (1), includes a history, physical exam, mental health screening, and laboratory screening for infectious conditions such as intestinal parasites, TB, syphilis, human immunodeficiency virus (HIV), and hepatitis B. Depending on age, medical history, and other risk factors, the refugees also are assessed for noninfectious conditions such as diabetes, hypertension, hyperlipidemia, anemia, and lead poisoning. This report describes prevalences for selected infectious and noninfectious conditions among Iraqi refugees in California, based on data from those assessments.

San Diego County received 5,397 (81%) of the 6,626 Iraqi refugees who resettled in California during FYs 2008 and 2009 (Table 1). Of these, 5,100 (94.5%) completed at least part of a medical assessment (Table 2), with a median time between arrival and assessment of 76 days (range: 1–159 days). Denominators varied for different components of the medical assessment because of screening criteria (e.g., age) and missing data. Although mental health screening was performed, the data captured were limited and are not presented here.

LTBI was identified in 692 (14.1%) of 4,923 of Iraqi refugees aged >1 year (Table 2). Within the subset of this group aged ≥65 years, the prevalence of LTBI was 52.3%. The only pathogenic intestinal parasites identified by stool examination were Giardia intestinalis in 40 (3.1%)and Entamoeba histolytica in 55 (1.2%) of 4,520 screened refugees; no helminths were identified. All other identified species were of little or indeterminate clinical significance (e.g., Endolimax nana and Blastocystis hominis, respectively) (3). Only 21 (0.7%) of 2,957 refugees of any age were hepatitis B surface antigen-positive, an indication of chronic hepatitis B virus infection. Most resettled Iraqi refugees were screened for syphilis and HIV during the required overseas examination. Of 28,366 U.S.-bound Iraqi refugees screened overseas during FYs 2008 and 2009, 27 (0.1%) had syphilis, and only three (<0.1%) were HIV-infected (CDC, unpublished data, 2010). Among 323 Iraqi refugee arrivals in San Diego County who had not been screened overseas for syphilis, eight (2.5%) were found to have the disease. Among 274 arrivals who had not been screened overseas for HIV, only one was found to be infected (Table 2). Among refugees aged >18 years, the most frequently diagnosed noninfectious conditions were obesity in 751 (24.6%) of 3,047 persons and hypertension in 410 (15.2%) of 2,704 persons.* Among those aged ≥65 years, 83 (64.3%) of 129 were hypertensive (Table 2). Of refugees aged ≥40 years who were screened for hyperlipidemia, 114 (39.9%) of 286 had dyslipidemia.Of children aged <5 years with available anthropometric data, 23 (7.1%) of 322 were acutely malnourished and 348 (29.6%) of 1,175 women of childbearing age were anemic.§

1

Editorial Note

During the past 3 decades, the United States has received approximately 3 million refugees from diverse countries and regions of the world (4). During FYs 2008 and 2009, Iraqi refugees were the largest group to resettle in the United States, accounting for approximately 21% of all U.S.-resettled refugees.The traditional focus of refugee medical screening has been on communicable diseases (2), and the overseas refugee medical examination emphasizes transmissible illness such as active TB. However, Iraqi refugees were displaced from a middle-income country, where the health profile combines some infectious diseases prevalent in low-income countries (e.g., TB) with chronic conditions seen in the United States (e.g., obesity) (5). The prevalence of obesity among Iraqi adults (24.6%), for example, nearly equaled the prevalence of adult obesity (24.8%) among adult California residents (6). Medical screening after arrival provides an opportunity to identify important causes of morbidity among resettled refugees that might not have been discovered previously, and enables early referral for treatment and follow-up care.

This report highlights key clinical findings among Iraqi refugees in San Diego and provides screening considerations. Chronic, noninfectious conditions were prevalent in this population. This finding is supported by outside data; for example, in a 2009 survey of Iraqi refugees in Jordan and Syria, 41%–51% of refugees aged ≥18 years reported a diagnosis of chronic illness such as hypertension, diabetes, or cardiovascular disease (S. Doocy, Johns Hopkins Bloomberg School of Public Health, personal communication, 2010). The epidemiology of some infectious diseases in Iraqi refugees also might differ from other refugee groups. For example, although the prevalence of LTBI in Iraqi refugees aged ≥65 years was comparable to rates in other refugee populations (7), recent data from the overseas medical examination indicate that prevalences of abnormal chest radiograph (0.7%) and culture-confirmed TB (0%) among 28,366 Iraqi refugees resettling to the United States during FYs 2008 and 2009 were much lower than those in other recently resettled refugee populations (8). Prevalence of chronic hepatitis B virus infection also was lower (0.7%) than country estimates (9) for Iraq (2%–7%) and substantially lower than prevalences seen in some sub-Saharan African and Southeast Asian refugee populations, which have been as high as 15% (10).

Few screened Iraqi refugees had evidence of pathogenic intestinal parasites on stool examination (G. intestinalis in 3.1% and E. histolytica in 1.2%). Although Iraqi refugees resettling to the United States from Jordan and Iraq routinely receive presumptive antihelminthic treatment with albendazole (1), none of the Iraqi refugees assessed in San Diego County during FYs 2008 and 2009 (including those from Syria, Lebanon, Turkey, and other countries without presumptive therapy) had evidence of intestinal helminths on stool microscopy. In contrast, other resettling refugee populations have had rates of pathogenic intestinal helminths (e.g., Ascaris spp., Trichuris spp., Ancylostoma spp., and Necator americanus) (3) as high as 24% (2). However, a recent serologic study of 200 Iraqi refugees found that up to 10% were infected with strongyloides and 3.5% with Schistosoma haematobium (CDC, unpublished data, 2009). Stool examination is not a sensitive tool for detection of these parasites, which can cause infection leading to serious health consequences, including death (3).

The health profile described in this report can help local, state, federal, and international public and refugee health agencies identify public health needs of Iraqi refugees resettling in the United States, and provide clinicians with information about relevant medical needs. Considerations for state public health agencies and clinicians include the importance of evaluation for obesity, hypertension, and dyslipidemia during state medical assessments, with careful screening for diabetes and heart disease among those with risk factors, followed by appropriate referral. Culturally appropriate programs should be implemented to promote obesity prevention and control among Iraqi refugees.

Testing for LTBI should be encouraged and treatment offered to persons with positive test results. Immunization programs in Iraq include bacille Calmette-Guerin vaccination, but CDC guidelines state that prior immunization should not be considered in the interpretation of a positive tuberculin skin test or interferon gamma release assay for TB infection (1). In addition, clinicians should consider presumptive treatment or serologic screening for strongyloidiasis and schistosomiasis (3), recognizing that the single albendazole dose provided during presumptive treatment in Iraq and Jordan would not eradicate either parasite.

Although rates of chronic malnutrition appear low among Iraqi refugee children aged <5 years, some young children might be acutely malnourished, perhaps because of sudden changes in food availability. In addition to routine assessment of nutritional status with anthropometric measurements and screening for anemia, clinicians should evaluate children aged <5 years for clinical signs of acute malnutrition, such as wasting or bilateral edema.

The findings in this report are subject to at least three limitations. First, the medical assessment was limited to the screening described in this report, the results of which might lead to referral for further workup. Therefore, diagnosis of other conditions anecdotally reported in this group of refugees by overseas health-care providers, such as cancers, ischemic heart disease, specific mental health diagnoses, and familial Mediterranean fever, is beyond the scope of the initial assessment. Past medical and family histories, and screening results for some sexually transmitted diseases (i.e., gonorrhea, chlamydia), also were not captured in these data. Second, Iraqi asylees were included in this group of refugees, and their profiles might differ slightly because they sought asylum after arrival in the United States and therefore did not receive predeparture medical examinations. Finally, many refugees were assessed >90 days after arrival; therefore, the original severity of certain conditions might not be reflected (e.g., degree of lead poisoning or presence of intestinal parasitic infections). Delays in medical assessment occurred because the health department was not prepared for the marked increase in Iraqi refugee arrivals during FYs 2008 and 2009 (U.S. arrivals increased from approximately 200 in FY 2007 to approximately 10,000 in FY 2008).

CDC and state public health departments should continue to collaborate to improve collection, review, and sharing of health data for arriving refugee populations. Timely data collection is a corollary of timely medical assessment. Improved planning for and communication regarding sudden increases in refugee arrival could help reduce the time to assessment and allow for earlier detection and referral of important medical conditions. A comprehensive and evidence-based understanding of the unique health profile of each incoming refugee population ultimately would allow development of beneficial, population-specific, and cost-effective screening and therapeutic guidelines for refugees.

References

  1. CDC. Medical examination of immigrants and refugees [Internet site]. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/immigrantrefugeehealth/exams/medical-examination.html. Accessed April 30, 2010.
  2. Barnett ED. Infectious disease screening for refugees resettled in the United States. Clin Infect Dis 2004;39:833–41.
  3. CDC. Domestic intestinal parasite guidelines [Internet site]. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/intestinal-parasites-domestic.html#table2. Accessed August 17, 2010.
  4. US Department of State. FY 2010 cumulative summary of refugee admissions. Washington, DC: US Department of State, Refugee Processing Center; 2010. Available at http://www.wrapsnet.org/reports/archives/tabid/215/language/en-us/default.aspxExternal Web Site Icon. Accessed April 29, 2010.
  5. Arredondo A. Costs and financial consequences of the changing epidemiological profile in Mexico. Health Policy 1997;42:39–48.
  6. CDC. U.S. obesity trends, 2009. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/obesity/data/trends.html#state. Accessed December 13, 2010.
  7. Varkey P, Jerath AU, Bagniewski SM, Lesnick TG. The epidemiology of tuberculosis among primary refugee arrivals in Minnesota between 1997 and 2001. J Travel Med 2007;14:1–8.
  8. Liu Y, Weinberg MS, Ortega LS, Painter JA, Maloney SA. Overseas screening for tuberculosis in U.S.-bound immigrants and refugees. N Engl J Med 2009;360:2406–15.
  9. CDC. The pre-travel consultation: hepatitis B. In: Health information for international travel 2010. Atlanta, GA: US Department of Health and Human Services, Public Health Service, 2009. Available at http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/hepatitis-b.aspx. Accessed April 29, 2010.
  10. Rein RB, Lesesne SB, O’Fallon A, Weinbaum CM. Prevalence of hepatitis B surface antigen among refugees entering the United States between 2006 and 2008. Hepatology 2010;51:431–4.

 

In recent years, Iraqi refugees have been resettling in the United States in large numbers, with approximately 28,000 arrivals during October 2007–September 2009 (federal fiscal years [FYs] 2008 and 2009). All refugees undergo a required medical examination before departure to the United States to prevent importation of communicable diseases, including active tuberculosis (TB), as prescribed by CDC Technical Instructions (1). CDC also recommends that refugees receive a more comprehensive medical assessment after arrival, which typically occurs within the first 90 days of arrival. To describe the health profile of resettled Iraqi refugees, post-arrival medical assessment data were reviewed for 5,100 Iraqi refugees who underwent full or partial assessments at the San Diego County refugee health clinic during FYs 2008 and 2009. Among 4,923 screened refugees aged >1 year, 692 (14.1%) had latent tuberculosis infection (LTBI); among 3,047 screened adult refugees aged >18 years, 751 (24.6%) were classified as obese; and among 2,704 screened adult refugees, 410 (15.2%) were hypertensive. Although infectious illness has been the traditional focus of refugee medical screening (2), a high prevalence of chronic, noninfectious conditions that could lead to serious morbidity was observed among Iraqi refugees. Public health agencies should be aware of the potentially diverse health profiles of resettling refugee groups. Medical assessment of arriving refugee populations, with timely collection and review of health data, enables early detection, treatment, and follow-up of conditions, and can help public health agencies develop and set priorities for population-specific health interventions and guidelines.

During FYs 2008 and 2009, California received 24% (6,626) of all U.S.-bound Iraqi refugees, the largest proportion of any state (Figure). The California Refugee Health Program provides comprehensive, standardized medical assessments for all refugees within 90 days of arrival. Based on those assessment results, refugees are referred to primary-care providers and, if needed, for specialized care. This initial assessment, based partially on CDC guidelines for arriving refugees (1), includes a history, physical exam, mental health screening, and laboratory screening for infectious conditions such as intestinal parasites, TB, syphilis, human immunodeficiency virus (HIV), and hepatitis B. Depending on age, medical history, and other risk factors, the refugees also are assessed for noninfectious conditions such as diabetes, hypertension, hyperlipidemia, anemia, and lead poisoning. This report describes prevalences for selected infectious and noninfectious conditions among Iraqi refugees in California, based on data from those assessments.

San Diego County received 5,397 (81%) of the 6,626 Iraqi refugees who resettled in California during FYs 2008 and 2009 (Table 1). Of these, 5,100 (94.5%) completed at least part of a medical assessment (Table 2), with a median time between arrival and assessment of 76 days (range: 1–159 days). Denominators varied for different components of the medical assessment because of screening criteria (e.g., age) and missing data. Although mental health screening was performed, the data captured were limited and are not presented here.

LTBI was identified in 692 (14.1%) of 4,923 of Iraqi refugees aged >1 year (Table 2). Within the subset of this group aged ≥65 years, the prevalence of LTBI was 52.3%. The only pathogenic intestinal parasites identified by stool examination were Giardia intestinalis in 40 (3.1%)and Entamoeba histolytica in 55 (1.2%) of 4,520 screened refugees; no helminths were identified. All other identified species were of little or indeterminate clinical significance (e.g., Endolimax nana and Blastocystis hominis, respectively) (3). Only 21 (0.7%) of 2,957 refugees of any age were hepatitis B surface antigen-positive, an indication of chronic hepatitis B virus infection. Most resettled Iraqi refugees were screened for syphilis and HIV during the required overseas examination. Of 28,366 U.S.-bound Iraqi refugees screened overseas during FYs 2008 and 2009, 27 (0.1%) had syphilis, and only three (<0.1%) were HIV-infected (CDC, unpublished data, 2010). Among 323 Iraqi refugee arrivals in San Diego County who had not been screened overseas for syphilis, eight (2.5%) were found to have the disease. Among 274 arrivals who had not been screened overseas for HIV, only one was found to be infected (Table 2). Among refugees aged >18 years, the most frequently diagnosed noninfectious conditions were obesity in 751 (24.6%) of 3,047 persons and hypertension in 410 (15.2%) of 2,704 persons.* Among those aged ≥65 years, 83 (64.3%) of 129 were hypertensive (Table 2). Of refugees aged ≥40 years who were screened for hyperlipidemia, 114 (39.9%) of 286 had dyslipidemia.Of children aged <5 years with available anthropometric data, 23 (7.1%) of 322 were acutely malnourished and 348 (29.6%) of 1,175 women of childbearing age were anemic.§

Research: Psychological Distress

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5949a5.htm?s_cid=mm5949a5_e

QuickStats: Percentage of Adults Aged ≥18 Years Who Experienced Serious Psychological Distress During the Preceding 30 Days,* by Sex and Age Group — National Health Interview Survey, 2009

Weekly

December 17, 2010 / 59(49);1621

* Six psychological distress questions are included in the National Health Interview Survey. Respondents are asked separate questions about how often during the preceding 30 days they felt 1) so sad that nothing could cheer them up, 2) hopeless, 3) worthless, 4) that everything was an effort, 5) nervous, or 6) restless or fidgety. Respondents can choose from among five response categories: all of the time, most of the time, some of the time, a little of the time, or none of the time. For this analysis, response values of 0 to 4 were assigned to each of the five response categories (with all of the time assigned 4 and none of the time assigned 0). The response values were summed to yield a scale with a 0–24 range. A value of 13 or more on this scale was used to define experiencing serious psychological distress.

 

Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population and are derived from the National Health Interview Survey sample adult component.

 

§ 95% confidence interval.

 

In 2009, women were more likely than men to experience serious psychological distress during the preceding 30 days (3.6% versus 2.8%). Among women, those aged 45–64 years were more likely (4.6%) to experience serious psychological distress than those aged 65–74 years (2.4%) and ≥75 years (2.7%). Among men, those aged 65–74 years (1.0%) were less likely to experience serious psychological distress than those aged 18–44 years (3.1%) and 45–64 years (2.9%).

 

Source: National Health Interview Survey, 2009 data. Available at http://www.cdc.gov/nchs/nhis.htm.

 

Alternate Text: The figure above shows the percentage of adults aged ≥18 years who experienced serious psychological distress during the preceding 30 days, by sex and age group in 2009. In 2009, women were more likely than men to experience serious psychological distress during the preceding 30 days (3.6% versus 2.8%). Among women, those aged 45-64 years were more likely (4.6%) to experience serious psychological distress than those aged 65-74 years (2.4%) and ≥75 years (2.7%). Among men, those aged 65-74 years (1.0%) were less likely to experience serious psychological distress than those aged 18-44 years (3.1%) and 45-64 years (2.9%).